Aligos Therapeutics (ALGS) EBIT Margin (2021 - 2026)
Aligos Therapeutics' (ALGS) quarterly EBIT Margin came in at 951.55% in Q1 2026, up 523591.0% on a YoY basis from N/an in Q1 2025, and up 92.63% quarter-over-quarter from 12907.69% in Q4 2025.
Powered by 
Analysis
Aligos Therapeutics (ALGS) EBIT Margin (2021 - 2026) Analysis & Trends
Aligos Therapeutics (ALGS) has reported EBIT Margin for 6 consecutive years, with 951.55% the latest figure, recorded in Q1 2026.
- For the quarter ending Q1 2026, EBIT Margin rose 523591.0% year-over-year to 951.55%; the trailing twelve-month figure through Jun 2026 stood at 2112.14% (up 39437.0% YoY), and the FY2025 full-year result was 4024.93%, down 155598.0% from the prior year.
- EBIT Margin climbed to 951.55% in Q1 2026 per ALGS's latest filing, from 12907.69% in the prior quarter.
- Across five years, EBIT Margin topped out at 445.76% in Q2 2023 and bottomed at 12907.69% in Q4 2025.
- Historically, EBIT Margin has averaged 2532.77% across 5 years, with a median of 1383.0% in 2022.
- The sharpest annual moves came in 2022 and 2025: EBIT Margin soared 969878 bps in 2022, then sank 951446 bps in 2025.
- Over 5 years, EBIT Margin stood at 641.28% in 2022, then plunged by 102 bps to 1294.03% in 2023, then tumbled by 162 bps to 3393.23% in 2024, then plunged by 280 bps to 12907.69% in 2025, then surged by 93 bps to 951.55% in 2026.
- According to Business Quant data, EBIT Margin over the past three periods registered 951.55%, 12907.69%, and 3827.4% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 34.95% |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | -133.21% |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 37.40% |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 30.15% |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 32.54% |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | -562.07% |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 17.93% |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | -23.56% |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | -25,380.93% |
| 10 | Aligos Therapeutics | 54.92 Mn | 24.48 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | -951.55% |
| Dec 31, 2025 | -12,907.69% |
| Sep 30, 2025 | -3,827.40% |
| Jun 30, 2025 | -1,924.04% |
| Mar 31, 2025 | -6,187.46% |
| Dec 31, 2024 | -3,393.23% |
| Sep 30, 2024 | -1,610.48% |
| Jun 30, 2024 | -2,489.54% |
| Mar 31, 2024 | -3,176.66% |
| Dec 31, 2023 | -1,294.03% |
| Sep 30, 2023 | -885.38% |
| Jun 30, 2023 | -445.76% |
| Mar 31, 2023 | -925.98% |
| Dec 31, 2022 | -641.28% |
| Sep 30, 2022 | -461.47% |
| Jun 30, 2022 | -552.21% |
| Mar 31, 2022 | -1,383.00% |
| Dec 31, 2021 | -10,340.05% |
| Sep 30, 2021 | -2,151.46% |
| Jun 30, 2021 | -1,913.59% |